Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

[1]  R. DeFronzo,et al.  The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone , 2009, Diabetes Care.

[2]  Carine Poussin,et al.  Glucagon-Like Peptide-1 Protects β-Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop , 2009, Diabetes.

[3]  J. Agudo,et al.  IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice , 2008, Diabetologia.

[4]  A. Lusis,et al.  Identification of ALOX5 as a gene regulating adiposity and pancreatic function , 2008, Diabetologia.

[5]  B. Ahrén.  Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin , 2008, Vascular health and risk management.

[6]  P. Pérez-Piñera,et al.  Pleiotrophin, A Multifunctional Tumor Promoter Through Induction of Tumor Angiogenesis, Remodeling of the Tumor Microenvironment, and Activation of Stromal Fibroblasts , 2007, Cell cycle.

[7]  P. Butler,et al.  The replication of β cells in normal physiology, in disease and for therapy , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[8]  D. Drucker.  Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes , 2007, Diabetes Care.

[9]  C. Cobelli,et al.  Effect of adding sitagliptin, a dipeptidyl peptidase‐4 inhibitor, to metformin on 24‐h glycaemic control and β‐cell function in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[10]  M. Papotti,et al.  Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-Kinase/Akt signaling. , 2007, Endocrinology.

[11]  J. Agudo,et al.  Expression of IGF-I in Pancreatic Islets Prevents Lymphocytic Infiltration and Protects Mice From Type 1 Diabetes , 2006, Diabetes.

[12]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[13]  Yue Feng,et al.  Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes , 2006, Diabetes.

[14]  N. Tajima,et al.  Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats , 2006, Diabetologia.

[15]  C. Ariyan,et al.  Inhibition of apoptosis by survivin improves transplantation of pancreatic islets for treatment of diabetes in mice , 2006, EMBO reports.

[16]  P. Flatt,et al.  Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[17]  R. Mentlein,et al.  Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes , 2005, Diabetologia.

[18]  M. Kanter,et al.  Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. , 2005, Pharmacological research.

[19]  Eberhard Standl,et al.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.

[20]  W. Soeller,et al.  Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. , 2003, Diabetes.

[21]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. , 2002, Biochemical and biophysical research communications.

[22]  E. Ayuso,et al.  β cell expression of IGF-I leads to recovery from type 1 diabetes , 2002 .

[23]  M. Permutt,et al.  Activation of Elk-1, an Ets transcription factor, by glucose and EGF treatment of insulinoma cells. , 2001, American journal of physiology. Endocrinology and metabolism.

[24]  I. Park,et al.  Clusterin expression during regeneration of pancreatic islet cells in streptozotocin-induced diabetic rats , 2001, Diabetologia.

[25]  E. Mannucci,et al.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. , 2001, Diabetes care.

[26]  I. Park,et al.  Antisense Oligonucleotide of Clusterin mRNA Induces Apoptotic Cell Death and Prevents Adhesion of Rat ASC-17D Sertoli Cells , 2000, Molecules and cells.

[27]  Yong Y. He,et al.  Upregulation of Pleiotrophin Gene Expression in Developing Microvasculature, Macrophages, and Astrocytes after Acute Ischemic Brain Injury , 1998, The Journal of Neuroscience.

[28]  C. Finch,et al.  Purification and characterization of brain clusterin. , 1994, Biochemical and biophysical research communications.

[29]  M. Peitsch,et al.  Overexpression of deoxyribonuclease I (DNase I) transfected into COS-cells: its distribution during apoptotic cell death. , 1993, European journal of cell biology.

[30]  D. Porte.  β-cells in type II diabetes mellitus , 1991, Diabetes.

[31]  L. Frohman,et al.  Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. , 1989, The Journal of clinical investigation.

[32]  W. Zeng,et al.  Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. , 2006, Clinical therapeutics.

[33]  C. Pilarsky,et al.  Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.